Catalog No.
DHJ64001
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
SLAMF7, CRACC, Protein 19A, SLAM family member 7, CD2-like receptor-activating cytotoxic cells, Membrane protein FOAP-12, CD319, Novel Ly9, CD2 subset 1, CS1
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9NQ25
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
BMS-901608, PDL063, HuLuc63, CAS: 915296-00-3
Clone ID
Elotuzumab
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma, PMID: 30403938
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma, PMID: 26035255
The Clinical Pharmacology of Elotuzumab, PMID: 28779463
Elotuzumab, PMID: 31644037
Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma, PMID: 30232695
Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma, PMID: 30455698
Elotuzumab, PMID: 29999843
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial, PMID: 33357482
The role of elotuzumab in the treatment of relapsed or refractory multiple myeloma, PMID: 29317395
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study, PMID: 32887873
Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma, PMID: 31679403
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial, PMID: 30204239
Elotuzumab: First Global Approval, PMID: 26809244
Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling, PMID: 29531651
Elotuzumab as a novel anti-myeloma immunotherapy, PMID: 28604269
Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment, PMID: 27493709
Elotuzumab-based maintenance therapy following autologous stem cell transplant in multiple myeloma deepens post-transplant responses, PMID: 32745939
Development of [ 89 Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma, PMID: 33179150
Elotuzumab for the treatment of multiple myeloma, PMID: 27417553
Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients' selection and perspective, PMID: 31410026
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM, PMID: 27091875
Efficacy and safety of elotuzumab for the treatment of multiple myeloma, PMID: 28060563
Elotuzumab in multiple myeloma, PMID: 30449660
Multiple Myeloma: Diagnosis and Treatment, PMID: 26763514
Second elotuzumab triplet efficacious in MM, PMID: 30478425
Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab, PMID: 27695618
Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date, PMID: 27785050
Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma, PMID: 27806428
Elotuzumab: a novel immune-stimulating therapy to treat multiple myeloma, PMID: 27322214
Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma, PMID: 24151843
Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab, PMID: 27083916
Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma, PMID: 27533882
Toward further simplification of elotuzumab therapy by subcutaneous administration, PMID: 32656639
Treatment of relapsed and refractory multiple myeloma, PMID: 32719176
Model-Based Determination of Elotuzumab Pharmacokinetics in Japanese Patients With Multiple Myeloma Incorporating Time-Varying M Protein, PMID: 32656777
Treatment of relapsed multiple myeloma: Evidence-based recommendations, PMID: 31500848
Mechanisms of Action and Clinical Development of Elotuzumab, PMID: 29272564
Elotuzumab in the treatment of relapsed and refractory multiple myeloma, PMID: 33478270
Frequent occurrence of hypophosphatemia among multiple myeloma patients treated with elotuzumab: a single clinic retrospective study, PMID: 33237342
Sequence matters: elotuzumab more effective if used before daratumumab, PMID: 31845607
How to Integrate Elotuzumab and Daratumumab Into Therapy for Multiple Myeloma, PMID: 27998219
Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab, PMID: 29996069
Elotuzumab for the treatment of multiple myeloma, PMID: 24941981
Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma, PMID: 24053207
Emerging immunotherapies in multiple myeloma, PMID: 32958461
Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy, PMID: 30147690
Elotuzumab: The First Monoclonal Antibody for the Treatment of Multiple Myeloma, PMID: 29282429
A review discussing elotuzumab and its use in the second-line plus treatment of multiple myeloma, PMID: 29091475
Soluble SLAMF7 is a predictive biomarker for elotuzumab therapy, PMID: 32398792
Elotuzumab-induced interstitial lung disease: the first case report, PMID: 29635485
For research use only. Not for human or drug use.
